Table 1. List of clinical trials included in the meta-analysis.

	Reference	Phase	Histology	Masking	No. patients (safety data)	Treatment arms
1	Reck M, et al. (2016)	3	Small cell lung cancer (SCLC)	Double-blind	954	Platinum + Etoposide + Placebo
						Platinum + Etoposide + Ipilimumab
2	Reck M, et al. (2012)	2	SCLC	Double-blind	128	Paclitaxel + Carboplatin + Placebo
						(Paclitaxel + Carboplatin + Placebo) followed by (Paclitaxel + Carboplatin + Ipilimumab)
						(Paclitaxel + Carboplatin + Ipilimumab) followed by (Paclitaxel + Carboplatin + Placebo)
3	Lynch TJ, et al. (2012)	2	Non-small cell lung cancer	Double-blind	203	Paclitaxel + Carboplatin + Placebo
						(Paclitaxel + Carboplatin + Placebo) followed by (Paclitaxel + Carboplatin + Ipilimumab)
						(Paclitaxel + Carboplatin + Ipilimumab) followed by (Paclitaxel + Carboplatin + Placebo)
4	Govindan R, et al. (2017)	3	NSCLC (Squamous-Sq-)	Double-blind	948	Paclitaxel + Carboplatin + Placebo
						(Paclitaxel + Carboplatin + Placebo) followed by (Paclitaxel + Carboplatin + Ipilimumab)
5	Langer CJ, et al. (2016)	2	NSCLC (Non-Sq)	Open-label	121	Carboplatin + Pemetrexed
						Carboplatin + Pemetrexed + Pembrolizumab
6	Hersh EM, et al. (2011)	2	Melanoma	Open-label	74	Ipilimumab
						Ipilimumab + Dacarbazine
7	Robert C, et al. (2011)	3	Melanoma	Double-blind	498	Placebo + Dacarbazine
						Ipilimumab + Dacarbazine
8	Weber J, et al. (2013)	1	Melanoma	Open-label	59	Ipilimumab
						Ipilimumab + Dacarbazine
						Ipilimumab + Paclitaxel + Carboplatin
9	Gandhi L, et al. (2018)	3	NSCLC (Non-Sq)	Double-blind	607	Platinum + Pemetrexed + Placebo
						Platinum + Pemetrexed + Pembrolizumab
10	Socinski MA, et al. (2018)	3	NSCLC (Non-Sq)	Open-label	787	Bevacizumab + Paclitaxel + Carboplatin
						Atezolizumab + Bevacizumab + Paclitaxel + Carboplatin
						Atezolizumab + Paclitaxel + Carboplatin (results not reported)